[CVS] CVS Health: Q3 2026 Earnings Test Aetna's Margin Recovery

CVS Health is one of the largest integrated health care companies in the United States, combining Aetna health insurance, the Caremark pharmacy benefit manager (PBM) and roughly 9,000 CVS retail pharmacies[1]. Its CVS Q3 2026 earnings call is scheduled for 2026-11-04 and will cover the Third quarter 2026 (three months ended September 30, 2026)[2]. In the latest disclosed period, the second quarter of 2026, total revenues rose 7.3% to $106.096 billion, GAAP operating income reached $4.703 billion versus $2.381 billion a year earlier, and adjusted EPS was $2.58 versus $1.81, while the medical benefit ratio (MBR) in the Health Care Benefits segment fell from 89.9% to 87.4%[3][4]. On August 5 the company raised its 2026 adjusted EPS guidance to $7.90-$8.10, with total revenues of at least $414 billion and cash flow from operations of at least $11.5 billion[3][5]; first-quarter adjusted EPS was $2.57, so the first half totaled $5.15 and the full-year range implies $2.75-$2.95 for the second half[6]. Analyst estimates compiled by Drillr on 2026-10-21 put third-quarter adjusted EPS at $1.66 (16 analysts, range $1.58-$1.72), revenue at $104.72 billion (12 analysts) and full-year EPS at $8.02; readers should note that the equivalent estimates for the prior two quarters, $2.18 and $1.85, both sat well below actual results of $2.57 and $2.58[7].

Three things matter most in this report. First, whether Aetna's medical benefit ratio keeps improving year over year: the first-half MBR was 86.0% versus 88.6% a year earlier, but part of that gain reflects the absence of prior-year premium deficiency reserves, management remains cautious on second-half medical cost trends, and the low end of the $5.03 billion full-year Health Care Benefits adjusted operating income guidance would allow a second-half loss of about $440 million[4][3][5]. Second, whether Caremark can keep profits growing under new 340B restrictions: Health Services adjusted operating income rose 10.0% to $1.733 billion in the second quarter, but management acknowledged that 340B already weighed on the quarter, that the pressure was offset only by value pulled forward from the second half and outperformance elsewhere, and that it would lay out 2027 headwinds and tailwinds on the third-quarter call[4][5]. Third, whether the retail pharmacy can keep growing once the prescription gains from Rite Aid enter the year-ago base: same-store prescription volume rose 7.0% and Pharmacy & Consumer Wellness adjusted operating income rose 10.2% in the second quarter, while full-year guidance of at least $6.4 billion requires second-half profit about $340 million above the second half of 2025[4][5][1].

Company Background and Business Structure

CVS Health is a health care group that puts health insurance, pharmacy benefit management and retail pharmacy inside one company. Headquartered in Woonsocket, Rhode Island, it was founded in 1963, renamed from CVS Caremark Corporation in 2014, acquired Aetna in 2018 and in 2023 bought in-home health evaluation company Signify Health and Oak Street Health, a primary care operator serving Medicare patients; David Joyner is chairman and CEO[8]. At the end of 2025 the company had about 9,000 retail locations and more than 1,000 clinics, Caremark served about 87 million plan members, and its insurance and related products served more than 37 million people; it reports four segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other[1].

Health Care Benefits is Aetna's insurance business, and its profit depends heavily on the gap between premium pricing and medical costs. Aetna sells medical, pharmacy and dental coverage to employers and to Medicare and Medicaid populations: in Insured products the company collects premiums and bears medical costs, while in ASC products the employer bears the risk and the company earns a fee; CMS pays Medicare Advantage plans a fixed capitation adjusted for membership and risk, and commercial Insured premiums are set at the start of the policy year, so cost overruns can usually be recovered only when the next year is priced[1]. Aetna exited the individual public exchanges in January 2026, and as of June 30, 2026 it had 26.023 million medical members, including 4.202 million in Medicare Advantage[1][4].

The other two operating segments are built around drugs, with larger revenue than the insurance segment but much thinner margins. Health Services includes the Caremark PBM, mail and specialty pharmacy, the Cordavis biosimilar business and care delivery businesses such as Signify Health and Oak Street Health; Pharmacy & Consumer Wellness runs the retail stores and infusion business, pharmacy revenue made up more than three-quarters of segment revenue in each year from 2023 to 2025, and the Omnicare long-term care pharmacy was deconsolidated in September 2025[1]. In fiscal 2025, segment revenues were $143.354 billion for Health Care Benefits, $190.425 billion for Health Services and $139.367 billion for Pharmacy & Consumer Wellness, with $71.563 billion of intersegment eliminations[1]; in the second quarter of 2026, consolidated revenue comprised $66.219 billion of products, $35.117 billion of premiums, $4.119 billion of services and $641 million of net investment income[4].

Financial History and Current Position

CVS grew revenue for three straight years, but profit fell sharply in fiscal 2024 on Aetna's losses and recovered only partly in fiscal 2025. Total revenues rose from $357.776 billion in fiscal 2023 to $372.809 billion in fiscal 2024 and $402.067 billion in fiscal 2025, while adjusted operating income fell from $17.534 billion to $11.976 billion before recovering to $14.443 billion[1]. By segment, Health Care Benefits adjusted operating income was $5.577 billion, $307 million and $2.939 billion over the three years, Health Services $7.312 billion, $7.243 billion and $7.151 billion, and Pharmacy & Consumer Wellness $5.963 billion, $5.774 billion and $6.040 billion, while the Corporate/Other loss widened from $1.318 billion to $1.687 billion[1]. Fiscal 2025 GAAP results also absorbed a $5.7 billion goodwill impairment for the Health Care Delivery reporting unit within Health Services[1].

Fiscal 2025 cash flow covered capital spending and dividends, but the company bought back no stock. Cash flow from operations was $10.639 billion, purchases of property and equipment were $2.832 billion and dividends paid were $3.397 billion; CVS repurchased $3.023 billion of stock in fiscal 2024 and none in fiscal 2025[1]. In the same year it issued $3.969 billion of long-term debt and repaid $3.629 billion, so debt barely shrank[1].

Profit in the first two quarters of 2026 was clearly better than a year earlier, mainly because of Aetna. First-quarter adjusted EPS was $2.57 versus $2.25, GAAP diluted EPS was $2.30 versus $1.41, and consolidated adjusted operating income was $5.150 billion versus $4.579 billion[6][9]. Second-quarter GAAP operating income was $4.703 billion versus $2.381 billion; net income attributable to CVS was $2.979 billion, or $2.31 per diluted share, while the prior-year GAAP result included $833 million of legacy litigation charges; consolidated adjusted operating income was $5.157 billion versus $3.808 billion[3][4].

The first-half cash improvement came partly from payment timing, and the company used the extra cash mainly to repay debt. Cash flow from operations was $10.594 billion in the first half of 2026, $4.1 billion more than a year earlier, which the company attributed to the timing of payments and receipts and better Health Care Benefits performance; over the same period it repaid $3.287 billion of long-term debt and paid $1.725 billion of dividends, and on June 30 it held about $11.3 billion of cash and equivalents, about $2.7 billion of it at the parent or nonrestricted subsidiaries[4]. Management said the 2026 guidance assumes no share repurchases and that it will evaluate capital deployment as leverage improves[5].

Operating Model

CVS revenue is driven by two main lines, prescription drug sales and premiums, and each responds to very different drivers. Consolidated revenue roughly equals product revenue (prescription drug sales at Caremark and CVS pharmacies, $66.219 billion in the second quarter of 2026) plus premiums ($35.117 billion) plus services ($4.119 billion) plus net investment income ($641 million), less intersegment eliminations[4]. Prescription revenue equals volume times price per prescription, with price shaped by brand inflation, drug mix (GLP-1s and specialty drugs) and generic substitution; premiums equal members times premium per member, and Medicare Advantage premiums depend on annual CMS rates and star bonuses, with final 2027 CMS rates implying a 2.48% average industry revenue increase excluding risk score trend[9].

Adjusted operating income is most sensitive to Aetna's medical benefit ratio, while the drug businesses earn margin per prescription times scale. Adjusted operating income roughly equals Aetna's premiums times (1 − MBR) plus fee revenue less operating expenses, plus Caremark's claims times margin per claim less operating expenses, plus pharmacy prescriptions times margin per prescription and front-store gross profit less store and staff costs, minus corporate costs[4]. On second-quarter 2026 premiums of $35.117 billion, each 1 percentage point change in MBR moves quarterly profit by about $350 million; GAAP operating income also deducts intangible amortization ($431 million pretax in the second quarter), litigation, goodwill impairment and restructuring items[4][3].

Cash flow swings widely from quarter to quarter because premiums arrive in advance, claims are paid later and drug rebates arrive with a delay. Premiums are collected monthly while medical claims are paid weeks to months after service, and as of June 30, 2026 liabilities for incurred-but-not-reported claims plus expected development totaled about $10.6 billion, with days claims payable at 41.7, down 1.2 days from March 31[4][3]. These timing effects lifted first-half cash flow from operations to $10.594 billion, while full-year guidance of at least $11.5 billion leaves only about $0.9 billion for the second half, which shows the company expects part of the first-half timing benefit to reverse[4][5].

The model works with clear lags, and several key variables are not disclosed. Commercial Insured cost overruns can only be recovered when the next year is priced, and Medicare Advantage benefits and pricing are reset once a year through the bid, so a change in medical costs usually hits current-year profit first and shows up in premiums about a year later[1]. The company does not disclose PBM margin per claim, rebate retention, the size of its 340B revenue or pharmacy margin per prescription, and it said only that its 2026 Health Services segment guidance is unchanged[5]. In addition, Health Care Benefits profit is usually weak in the fourth quarter because of Part D seasonality, which matters when reading the second-half guidance.

Industry and Competitive Position

CVS sits near the top of three parts of U.S. health care, and that integration brings both a cost advantage and regulatory scrutiny. Aetna is a national health insurer competing with UnitedHealth, Elevance, Humana and Cigna; Caremark, together with Cigna's Express Scripts and UnitedHealth's Optum Rx, makes up the three largest PBMs; and CVS Pharmacy is one of the national retail chains with the most stores, which picked up extra volume in 2025 through its acquisitions of Rite Aid prescription files[1]. Evidence management cited on the second-quarter call includes specialty pharmacy adherence above 90%, ahead of an 80% industry target, and retail prescription growth that has consistently outpaced the market[5].

Regulatory pressure on this integrated model is rising, and the available material does not support a quantitative comparison with competitors. On the first-quarter call management discussed the impact of Tennessee legislation on the pharmacy business and described the TrueCost pricing model[8]; on the second-quarter call it said new regulation and the proposed FTC settlement will accelerate the PBM shift toward net cost pricing models[5]. The competitors named above support only a qualitative comparison, because comparable margin and share data are outside CVS's own disclosures, so CVS's relative strengths rest mainly on the company's own figures.

Core Debates

Aetna cut its first-half MBR to 86.0% through Medicare pricing discipline; will second-half medical cost trends erode that margin recovery?

Health Care Benefits is CVS's most volatile segment, and whether it holds its recovery in the second half determines how credible the full-year guidance is. The segment's adjusted operating income fell from $5.577 billion in fiscal 2023 to $307 million in fiscal 2024 and recovered to $2.939 billion in fiscal 2025[1]. In the first half of 2026 it earned $5.467 billion, $2.166 billion more than a year earlier, and was the main reason consolidated adjusted EPS rose from a combined $4.06 to $5.15[3][6]. In the second quarter management raised the segment's full-year guidance by more than $1 billion to $5.03-$5.37 billion while keeping a cautious view of second-half medical cost trends[5].

Current evidence shows the first-half improvement came mainly from current performance in the Government business rather than from larger releases of prior-year reserves. The second-quarter MBR was 87.4% versus 89.9% a year earlier; the company attributed the gain to underlying Government business performance and the absence of a $471 million premium deficiency reserve booked in Group Medicare Advantage a year earlier, and the first quarter likewise benefited from the absence of a $448 million reserve in the individual exchange business[3][6]. Favorable prior-year reserve development was $1.2 billion in the first half, below $1.9 billion a year earlier; medical membership on June 30 was 26.023 million, about 700,000 below the 26.721 million a year earlier mainly because of the exchange exit, and Medicare Advantage membership was 4.202 million versus 4.267 million at the end of 2025[4]. Days claims payable fell from 42.9 on March 31 to 41.7[6][3].

The transmission behind the recovery is clear, but part of the first-half figure is a base effect that the second half may not repeat. Medicare Advantage bids for 2025 and 2026 trimmed benefits and raised pricing, and the company left the individual exchanges, so premium per member rose relative to medical cost and loss-making products dropped out; MBR therefore fell from 88.6% to 86.0% and segment adjusted operating income rose $2.166 billion year over year[4]. An alternative reading is that much of the first-half gain came from the reserve base and early-year prior-period releases, neither of which helps in the second half, while Part D costs concentrate later in the year and No Surprises Act arbitration costs rise, so the third-quarter MBR improvement could narrow sharply or even reverse; management, for its part, said the commercial cost pressure from a small group of providers abusing the arbitration process is already reflected in current guidance[5].

The third-quarter MBR and any change to segment guidance will directly test which of these readings is closer to the facts. Investors should watch whether the third-quarter MBR still improves year over year and how the company describes second-half cost trends, whether the $5.03-$5.37 billion segment guidance is kept, raised or cut, and whether prior-year reserve releases and days claims payable signal weaker earnings quality[5][4]. A year-over-year rise in third-quarter MBR or a guidance cut would show cost trends offsetting the gains from pricing discipline; an improving MBR with prior-year releases no higher than a year earlier would support the view that the recovery comes from current pricing.

Can Caremark keep profits growing through purchasing economics and specialty pharmacy as new 340B restrictions and client price concessions mount?

Health Services is CVS's largest profit source, and its profit depends on the spread between the client price, the purchase cost and rebate retention on each prescription, a spread that regulation and pricing-model changes are reshaping at the same time. The segment earned $7.151 billion of adjusted operating income in fiscal 2025, about 44% of the $16.130 billion combined total of the three operating segments; that profit fell 1.3% year over year, which the company attributed to continued client price improvements and a higher medical benefit ratio in its care delivery business, and pharmacy claims processed fell 0.9%[1]. On August 5, 2026 management said for the first time that 340B and renewal retention would weigh on Health Services profit in 2027[5].

Second-quarter results were still growing, but that growth combined real pressure with a one-time pull-forward. Segment revenue rose 11.5% to $51.795 billion, mainly on drug mix and brand inflation, and adjusted operating income rose 10.0% to $1.733 billion, which the company attributed to better purchasing economics, drug mix and modest improvement in care delivery, partly offset by client price improvements[3][4]. Pharmacy claims rose 0.9% to 473.0 million and mail and specialty revenue rose 15.1% to $22.577 billion, yet the adjusted operating margin slipped from 3.4% to 3.3%; first-quarter segment profit had fallen 7.1%, so the first-half total of $3.222 billion was only 1.4% above $3.178 billion a year earlier[4][6]. On the call management said the second quarter absorbed pressure from new 340B restrictions together with value originally expected in the second half arriving early, both offset by outperformance across the broader Caremark business, including higher specialty generic penetration, and that 2027 renewal retention is slightly below the company's historical average but in line with the industry[5].

Two opposing forces set this segment's profit, and 2027 client losses will only appear in claims volume early next year. Client renewal concessions, the shift to net cost pricing and manufacturer 340B restrictions reduce the margin retained per prescription; generic and biosimilar substitution, specialty dispensing and purchasing leverage reduce the cost per prescription, and the difference between the two determines Health Services adjusted operating income[5][1]. An alternative reading is that second-quarter growth relied partly on the pull-forward, so from the third quarter 340B pressure and the reversal of that early recognition could combine to turn Health Services negative year over year in the second half, with a further decline in 2027 as below-average retention and some health plan clients exiting products reduce volume[5].

Management's quantification of 2027 headwinds on the third-quarter call is the most important checkpoint in this debate. Investors should watch whether third-quarter Health Services adjusted operating income still grows year over year, whether mail and specialty revenue keeps growing at double digits, and how management sizes the 340B and renewal headwinds and whether it keeps its preliminary 2027 framework of adjusted EPS of at least $8.44; the company described $8.44 as 13% growth from its 2026 adjusted midpoint baseline and consistent with market expectations at the time[5]. A year-over-year profit decline in the third quarter would show purchasing economics can no longer cover concessions and 340B; growth with the 2027 framework intact would show the pressure remains within the company's expectations.

Once Rite Aid's prescription gains enter the year-ago base, can CVS Pharmacy keep growing volume and profit?

Pharmacy & Consumer Wellness is CVS's second-largest profit source, and its profit relies on prescription volume levering fixed store costs, so any slowdown in volume feeds straight into earnings. The segment earned $6.040 billion of adjusted operating income in fiscal 2025, when acquired Rite Aid prescription files added volume and same-store prescriptions rose 8.0% while same-store pharmacy sales rose 18.0%[1]. From the third quarter of 2026 those gains begin entering the year-ago base, yet the full-year segment guidance of at least $6.4 billion still requires roughly 10% profit growth in the second half[5].

Second-quarter performance remained strong, and management argues growth does not depend on Rite Aid alone. Segment revenue rose 0.7% to $33.816 billion, prescriptions filled rose 4.3% to 457.0 million, same-store prescription volume rose 7.0%, same-store pharmacy sales rose 2.9% and front-store same-store sales rose 1.0%; adjusted operating income rose 10.2% to $1.475 billion, which the company credited to core pharmacy performance and the Rite Aid asset acquisitions, partly offset by business investments and consumer conditions[4][3]. Measured as revenue less cost of products sold, the segment's second-quarter gross margin was about 19.3% versus about 17.9% a year earlier[4]. Management said CVS has consistently outgrown market prescription volume, that Rite Aid is only an extra tailwind in 2026, that gross margin progress is ahead of expectations and that the rollout of cost-plus reimbursement contracts is continuing[5]. Even so, first-half segment adjusted operating income of $2.672 billion was only 0.8% above $2.651 billion a year earlier, because first-quarter profit fell from $1.313 billion to $1.197 billion[4][9].

Volume growth converts into profit through operating leverage, while reimbursement pressure and regulatory price cuts squeeze margin per prescription from the other side. Prescriptions transferred after Rite Aid store closures and share gains from better service push volume up, creating leverage over fixed store costs and lifting segment profit; reimbursement pressure, regulatory price reductions and new generic launches compress margin per prescription, and cost-plus reimbursement contracts are meant to stabilize it[5][1]. An alternative reading is that first-half 2026 growth came mainly from transferred Rite Aid prescriptions, so once those gains enter the base same-store prescription growth falls back to low single digits while reimbursement pressure and negotiated drug prices keep squeezing margins, leaving second-half profit growth short of the roughly 10% the guidance requires.

Third-quarter same-store prescriptions and segment profit growth will show whether growth comes from share or from the acquisition. Investors should watch whether same-store prescription growth stays above 4%, whether segment adjusted operating income grows at least 5% and the at-least-$6.4 billion full-year guidance holds, and whether segment gross margin stays above the 2025 level[5][4]. Same-store prescription growth below 4% with profit growth under 5% would show growth depends on acquired volume; same-store growth above 4% with continued profit growth would support the share-gain explanation.

Risks and Falsifiers

PBM regulation could force Caremark and CVS Pharmacy to change their integrated model, and it is the company's largest structural risk. Tennessee's law barring PBMs from owning retail pharmacies, federal 340B and net cost pricing requirements, and the proposed FTC settlement management mentioned are reshaping PBM pricing at the same time[8][5]. The exposed lines are Health Services and Pharmacy & Consumer Wellness, which together contributed $13.191 billion of fiscal 2025 adjusted operating income, and management said only that the shift to net cost pricing will accelerate without quantifying the effect[1][5]. If the third-quarter call confirms that known regulatory changes are already reflected in the 2027 framework of adjusted EPS of at least $8.44, and the Tennessee litigation does not change how the company operates in that state, the real impact of this risk would be smaller than feared.

Lower Medicare Advantage star ratings would reduce quality bonuses one to two years later, so this risk arrives after the coming report. Based on December 2025 membership, more than 81% of Aetna's Medicare Advantage members are in 2026 plans rated 4 stars or higher and more than 63% are in a 4.5-star plan; 2026 stars set 2027 quality bonuses, and the 2027 stars published in October 2026 set 2028 bonuses[1]. Lower stars cut quality bonuses, which the company said could weaken benefits, reduce membership or compress margins, though it gave no figure; as of June 30, 2026 the exposed Medicare Advantage membership was 4.202 million, and the risk has no direct financial effect on the third quarter of 2026[1][4]. If the company says on its third- or fourth-quarter call that star changes are built into its 2028 margin targets, and later star coverage recovers, this risk would recede.

Second-half medical cost trends running above pricing assumptions are the most direct risk to 2026 results. Outpatient utilization, Part D costs concentrated late in the year and No Surprises Act arbitration could all slow Aetna's margin recovery in the third and fourth quarters[5]. On second-quarter premiums of $35.117 billion, each 1 percentage point of higher MBR cuts quarterly Health Care Benefits profit by about $350 million, and the gap between the $5.03 billion low end of full-year guidance and the $5.467 billion first-half result leaves room for a second-half loss of only about $440 million[4][5]. If MBR improves year over year in both the third and fourth quarters and full-year segment adjusted operating income is at least $5.03 billion, this risk will not have materialized.

340B restrictions, the move to net cost pricing and weaker renewal retention could combine to cut Caremark's 2027 profit by more than the rest of the company can offset. Health Services earned $7.151 billion of adjusted operating income in fiscal 2025[1]. The company has not disclosed the size of its 340B-related revenue; management said only that 2027 will be pressured and that it will lay out 2027 headwinds and tailwinds on the third-quarter call[5]. If formal 2027 guidance keeps adjusted EPS at $8.44 or more with the Health Services headwind quantified and included, this risk stays manageable.

Slower prescription growth after Rite Aid enters the base, combined with continued reimbursement pressure and regulatory price cuts, could stall pharmacy profit growth. Full-year segment guidance of at least $6.4 billion, less the first-half $2.672 billion, requires at least $3.728 billion in the second half, about $340 million more than the $3.389 billion earned in the second half of 2025; each percentage point of shortfall in second-half growth equals roughly $34 million of profit[5][4][1]. If segment adjusted operating income grows year over year in both the third and fourth quarters and reaches at least $6.4 billion for the year, this risk will not have materialized.

What to Watch Next

The checkpoints for the three core debates can be tracked against the 2026-11-04 release and the quarterly filing that follows[3][4][5].

• Aetna margin recovery: watch the third-quarter MBR against 87.4% in the second quarter (89.9% a year earlier) and 86.0% for the first half, the $5.03-$5.37 billion segment guidance, prior-year reserve releases against $1.2 billion in the first half ($1.9 billion a year earlier) and days claims payable against 41.7. A year-over-year MBR increase or a guidance cut would falsify the current view; an improving MBR with releases no higher than a year earlier would confirm it.
• Caremark under 340B: watch Health Services adjusted operating income against $1.733 billion (up 10.0%) and a 3.3% margin, mail and specialty revenue against $22.577 billion (up 15.1%), and the size of the 2027 340B headwind against the framework of at least $8.44 in 2027 adjusted EPS. A year-over-year profit decline would falsify the current view; growth with the 2027 framework intact would confirm it.
• Pharmacy after Rite Aid laps: watch same-store prescription growth against 7.0%, segment adjusted operating income against $1.475 billion (up 10.2%) and gross margin against about 19.3% (17.9% a year earlier), with full-year guidance of at least $6.4 billion. Same-store growth below 4% with profit growth under 5% would falsify the current view; meeting both thresholds would confirm it.

Conclusion

Three lines drive CVS results: the spread between Aetna's premiums and medical costs, the spread between Caremark's purchase cost and client price on each prescription, and the leverage that retail prescription volume creates over fixed store costs. In the first half of 2026 Aetna's MBR fell from 88.6% to 86.0% and segment profit rose $2.166 billion year over year, which led the company to raise full-year adjusted EPS guidance to $7.90-$8.10, and it used $10.594 billion of first-half operating cash flow to repay $3.287 billion of long-term debt[4][3]. The central unresolved relationship is whether a margin recovery built on pricing discipline can hold against second-half medical costs, and whether Caremark and the pharmacy can keep contributing growth under 340B, client concessions and the Rite Aid base effect[5].

Since the August 5 results there has been only one independent interpretation whose original text could be checked, and it both agrees and conflicts with management's account. In an August 29, 2026 article for TIKR, Gian Estrada argued that the second-quarter print itself was strong and that the problem sat in the outlook: the first 2027 number only matched market expectations at the time, 340B rules will pressure Caremark's 2027 profit and renewal retention is below its historical level, which he treated as a real headwind stacked against a 2026 that keeps beating[10]. Management also acknowledged that 340B and renewal retention will weigh on Health Services in 2027, but said those headwinds are already more than offset by strength elsewhere in the company and that its target of mid-teens adjusted EPS compound annual growth from 2025 through 2028 remains intact[5]. The disagreement is whether Caremark's pressure can be absorbed by the other segments, which maps directly to the second core debate. Beyond that, a broker estimate of the star-rating impact appeared only in secondhand reports, so outside interpretation remains thin overall.

Only a combination of operating and financial observations would change the understanding of CVS. If Aetna's third-quarter MBR keeps improving year over year without a cut to segment guidance, Health Services profit still grows while management quantifies the 2027 headwinds and keeps the framework of at least $8.44, and same-store prescription growth stays above 4%, the current recovery looks more likely to rest on durable pricing and share gains. Conversely, if MBR rises year over year, Health Services profit turns down, pharmacy profit growth falls below 5%, or the 2027 headwinds prove larger than the rest of the company can absorb, the first-half improvement would look more like the product of base effects and timing[5].

Sources

[1] CVS FY2025 10-K filed 2026-02-10 · 2026-02-10 · 10-K · https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/

[2] CVS earnings calendar updated 2026-10-21 · 2026-10-21 · Drillr earnings calendar

[3] CVS Q2 2026 8-K filed 2026-08-05 · 2026-08-05 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000064803&type=8-K&dateb=&owner=include&count=40

[4] CVS Q2 2026 10-Q filed 2026-08-05 · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/64803/000006480326000098/

[5] CVS Q2 2026 earnings call 2026-08-05 · 2026-08-05 · earnings-call · https://gateway.drillr.ai/mcp/private

[6] CVS Q1 2026 8-K filed 2026-05-06 · 2026-05-06 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000064803&type=8-K&dateb=&owner=include&count=40

[7] Drillr analyst estimates CVS Q3 2026 retrieved 2026-10-21 · 2026-10-21 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[8] CVS Q1 2026 earnings call 2026-05-06 · 2026-05-06 · earnings-call · https://gateway.drillr.ai/mcp/private

[9] CVS Q1 2026 10-Q filed 2026-05-06 · 2026-05-06 · 10-Q · https://www.sec.gov/Archives/edgar/data/64803/000006480326000052/

[10] TIKR CVS 2027 outlook review 2026-08-29 · 2026-08-29 · TIKR · https://www.tikr.com/blog/cvs-raised-2026-guidance-its-first-2027-number-is-what-spooked-the-market